Opaleye Management Inc.
SEC Form 4 history across 3 companies, 38 transactions and 14 filings.
Available history · May 27, 2026 – Oct 16, 2026
Latest insider transactions
Form 4 filings from available history.Latest Form 4 facts
Quick context from source filings
buy at Grace Therapeutics, Inc. on Oct 16, 2026 valued at $68,758.
Review SEC filingNo open-market insider sale is available.
Monthly open-market activity
Last 4 reported months · purchases and sales
View exact monthly values
| Month | Purchases | Sales | Buy value | Sale value | Net value |
|---|---|---|---|---|---|
| May 2026 | 3 | 0 | $434,713.77 | $0.00 | $434,713.77 |
| Aug 2026 | 6 | 0 | $2,814,532.35 | $0.00 | $2,814,532.35 |
| Sep 2026 | 20 | 0 | $2,339,537.97 | $0.00 | $2,339,537.97 |
| Oct 2026 | 9 | 0 | $289,679.67 | $0.00 | $289,679.67 |
Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.
Ownership and transaction size
Ownership and ticket size
Filing-only signals
Deterministic matches in this insider's history
Associated companies
Companies in the disclosed reporting history
Open-market buy performance
90-day forward return on this insider's open-market purchases
No purchases currently have the price observations needed for a 90-day return. This may reflect incomplete price coverage or purchases that have not reached the return window.
How reported shareholdings evolved
Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.
17 observations · Aug 14, 2026 – Oct 16, 2026. Window ends at the latest available report, not today.
View exact observations and source transactions
| Transaction date | Shares held after | Filed | Source |
|---|---|---|---|
| Aug 14, 2026 | 2,760,000 | Aug 19, 2026 | View transaction |
| Sep 8, 2026 | 2,769,393 | Sep 10, 2026 | View transaction |
| Sep 9, 2026 | 2,775,229 | Sep 10, 2026 | View transaction |
| Sep 21, 2026 | 2,850,000 | Sep 23, 2026 | View transaction |
| Sep 21, 2026 | 2,785,000 | Oct 1, 2026 | Amended transaction |
| Sep 23, 2026 | 2,855,318 | Sep 23, 2026 | View transaction |
| Sep 23, 2026 | 2,790,318 | Oct 1, 2026 | Amended transaction |
| Sep 29, 2026 | 2,798,167 | Oct 1, 2026 | View transaction |
| Oct 1, 2026 | 2,836,963 | Oct 5, 2026 | View transaction |
| Oct 2, 2026 | 2,856,963 | Oct 5, 2026 | View transaction |
| Oct 5, 2026 | 2,858,657 | Oct 5, 2026 | View transaction |
| Oct 8, 2026 | 2,860,734 | Oct 13, 2026 | View transaction |
| Oct 9, 2026 | 2,866,074 | Oct 13, 2026 | View transaction |
| Oct 12, 2026 | 2,873,289 | Oct 13, 2026 | View transaction |
| Oct 14, 2026 | 2,884,522 | Oct 17, 2026 | View transaction |
| Oct 15, 2026 | 2,908,007 | Oct 17, 2026 | View transaction |
| Oct 16, 2026 | 2,944,354 | Oct 17, 2026 | View transaction |
Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.
Opaleye Management Inc. Insider Activity FAQ
SEC Form 4 context
Who is Opaleye Management Inc.?
Opaleye Management Inc. is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001595855.
Which companies has Opaleye Management Inc. reported transactions for?
Grace Therapeutics, Inc., Alpha Cognition Inc., Sol-Gel Technologies Ltd., HARROW, INC., CODEXIS, INC.
When was Opaleye Management Inc.'s latest insider buy?
buy at Grace Therapeutics, Inc. on Oct 16, 2026 valued at $68,758.
When was Opaleye Management Inc.'s latest insider sale?
No open-market insider sale is available for this period.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.